

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort NeuroScientific Corporation

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

VOLUNTARY ANNOUNCEMENT
NUWISMEN® LIQUID EMBOLIC AGENT ENTERS
THE INNOVATIVE GREEN PATH OF NMPA

This announcement is made by MicroPort NeuroScientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company is pleased to announce that NuWismen® Liquid Embolic Agent developed by the Group, has passed the special review application for innovative medical devices of National Medical Products Administration (the “**NMPA**”) and entered the special review procedure (the “**Green Path**”). This selection marks the Group’s eighth product to be included in the NMPA’s special review for innovative medical devices, completing its product portfolio for the treatment of cerebral vascular malformations and further enhancing its ability to provide comprehensive interventional solutions across all scenarios involving cerebrovascular diseases.

Cerebral vascular malformations include common lesions such as brain arteriovenous malformations (bAVM) and dural arteriovenous fistulas (dAVF). For complex lesions that are deeply located, involve functional areas, or are complicated by aneurysms or high-flow fistulas, interventional embolization is the first choice in clinical treatment and an important means of combined therapy.

The Group is committed to the development and promotion of innovative medical solutions. It currently offers 29 neuro-interventional products covering major diseases such as aneurysms, stenosis, and thrombus extraction. Eight of the Group’s products have been included in the NMPA’s Green Path for innovative medical devices; the remaining seven are Tubridge® Flow Diverter, Bridge® Rapamycin Target Eluting Vertebral Stent System, Tigertriever® Revascularization Device, Rebridge® Intracranial Stent, StraitPass® Disposable Aspiration Neuroendoscope Device, Nufairy™ Absorbable Coil and Artemis Dream® Self-Expanding Intracranial Rapamycin Eluting Stent System, include three that have already been launched commercially.

There can be no assurance that NuWismen® Liquid Embolic Agent will eventually be successfully commercialized. Shareholders and potential investors of the Company should exercise caution when investing in the shares of the Company.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Tuesday, 1 September 2026. Trading in the shares of the Company on the Stock Exchange will remain suspended until further notice.

By Order of the Board
MicroPort NeuroScientific Corporation
Dr. Zhang Jie
Chairman and Non-executive Director

Hong Kong, 24 September 2026

As of the date of this announcement, the Board comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Dr. Zhang Jie, Mr. Liu Xudong and Ms. Wu Xia as the non-executive directors; Dr. Zhang Haixiao, Mr. Fan Xin, Mr. Li Zhiyong and Mr. Liu Thomas A. as the independent non-executive directors.